RU2517211C2 - Pharmaceutical composition, which contains enzyme deoxyribonuclease and glycyrrhizic acid or its salts: ammonium or dipotassium or trisodium glycyrrhizinate - Google Patents

Abstract

FIELD: medicine, pharmaceutics.

SUBSTANCE: claimed invention relates to medicine, namely to pharmaceutical composition, which contains enzyme deoxyribonuclease or glycyrrhizic acid or its salts: ammonium or dipotassium or trisodium glycyrrhizinate, which can be applied in medicine for treatment and prevention of viral infections, caused by DNA-containing viruses, such as herpes, shingles, human papilloma, adenoviruses, etc. In an invention claimed is a pharmaceutical composition, which includes as active ingredients - 0.001-0.5 wt % of deoxyribonuclease (DNA-ase) and 0.001-0.5 wt % of glycyrrhizic acid or its salts: ammonium or dipotassium or trisodium glycyrrhizinate, as carriers: β-cyclodextrins or lecithins 0.001-5.0 wt %, a polymer carrier 0.05-1.00 wt % and acceptable excipients.

EFFECT: obtaining the pharmaceutical composition, which contains enzyme deoxyribonuclease and glycyrrhizic acid.

3 cl, 7 ex, 2 tbl

Description

The present invention relates to medicine, namely to a pharmaceutical composition containing a deoxyribonuclease enzyme and glycyrrhizic acid or its salts: ammonium or dipotassium or trisodium glycyrrhizinate, which can be used in medicine for the treatment and prevention of viral infections caused by DNA-containing viruses, such as herpes, herpes zoster, human papilloma, adenoviruses and others.

There are known topical medicines used for the treatment and prevention of herpesvirus infections containing antiviral components that are not enzymes, for example, Zovirax ™ cream (acyclovir) (http://www.vidal.ru/poisk_preparatov/zovirax~27174.htm ); capsules and lyophilisate for the preparation of a solution for intravenous administration of Phosphogliv ™ (phospholipids and trisodium salt of glycyrrhizic acid) (http://www.vidal.ru/poisk_preparatov/phosphogliv.htm); Epigen-intim ™ spray (glycyrrhizic acid) (http://www.vidal.ru/poisk_preparatov/epigen-intim.htm); ointments: alpizarin (http://alpizarin.ru/), helepin (http://www.vidal.ru/poisk_preparatov/helepin-d_20830.htm), flacoside (http://ru.wikipedia.org/wiki/% D4% EB% E0% EA% EE% E7% E8% E4) containing plant extracts.

Known drug Interferon alpha-2a, identical to human leukocyte interferon alpha-2 and having immunomodulating, antiviral and antitumor effects. (Reference "Medicines" edited by M.A. Klyuyev 2001)

La-Cree ™ Lip Balm is a cosmetic product containing licorice extract and bisabolol, used to soften the skin of the lips. (http://vertex.spb.ru/catalog/68/34/la-kri_balyzam_dlya_gub.html)

Known lip balm Uriage Barierderm, containing shea butter, borage oil, unsaponifiable fractions of avocado oil, stearyl glycyrrhetinate, ascorbyl palmitate, tocopherol, used to repair damaged lip skin. (http://www.krason.ru/catalog-bariederm/1740-3620-balzam-dlya-gub.aspx?perf=1)

Known drug Glycyram (ammonium glycyrrrhizinate), used in the form of tablets for the treatment of bronchial asthma and adrenal hypofunction. (http://www.vidal.ru/poisk_preparatov/glycyram-tablets-0.05_27575.htm)

Known combination drug Hexalysis, containing as antimicrobial components - biclotimol and lysozyme, enoxolone isolated from glycyrrhizic acid as an anti-inflammatory component. (http://www.vidal.ru/poisk_preparatov/hexalyse~22640.htm)

There are known topical cosmetics used for the prevention of herpes containing antiviral components that are not enzymes, for example, extracts of medicinal plants and germanium-organic compounds (Antiherpetic preventative lipstick (P16 9158 915854 71.100.70) 292472. TU 9124-001- 00358210-96), glycyrrhizic acid ointment "Herpinat" ointment; ban. 20 ml; No. 77.01.12.915.P.02970.02.00 from the Research Institute of Atherosclerosis of the Russian Academy of Natural Sciences (Russia), INAT-PHARMA (Russia) (http://www.biomedservice.ru/publish/pub16.htm)

A cosmetic enzyme-containing composition is known where the enzyme is selected from the group of proteinases, including trypsin, chymotrypsin, bromelain, papain and ficin, as well as lysozyme, elastase, α-lipase and α-amylase, which is used to treat acne, care for skin and skin cleansing (DE 4305460). The described composition does not contain nuclease enzymes with direct antiviral activity, and therefore cannot be used to prevent viral infections.

Known pharmaceutical preparation "Deoxyribonuclease", produced in the form of lyophilized powder in hermetically sealed vials and ampoules of 0.005; 0.01; 0.025 and 0.05 g. This drug is prescribed for herpetic keratitis, adenoviral conjunctivitis, to reduce viscosity and improve the evacuation of sputum and pus in bronchiectasis and is used topically in the form of a 0.2% solution on isotonic sodium chloride solution (Reference "Medicines" edited by M.A. Klyuyev 2001).

Known pharmaceutical drug "Ribonuclease", produced in the form of lyophilized powder in hermetically sealed vials of 0.01 g. This drug is prescribed for diseases of the respiratory tract with difficult to separate sputum, periodontal disease, gingivitis, purulent wounds, trophic ulcers, tick-borne encephalitis, thrombophlebitis. topical application is sprinkled on the wound surface in the amount of 0.025-0.05 g (Reference "Medicines" edited by M.A. Klyuyev 2001).

From RU 2410123 C2, a composition is known containing 0.2-0.4 wt.% Deoxy ribonuclease (DNase) and acceptable carriers and excipients.

The difference between the claimed invention and RU 2410123 C2 is that the composition contains 0.001-0.5 wt.% Glycyrrhizic acid or its salts: ammonium or dipotassium or trisodium glycyrrhizinate and has a complex antiviral effect, which consists in interrupting the replication of the virus in the early stages, stimulating output virion from the capsid, hydrolysis of viral DNA and the induction of interferon formation, as well as the suppression of secondary microflora and inflammation in the affected area and the acceleration of epithelization.

From US 20090220440 A1 (lST FARMACOTERAPICO IT SPA), 09/03/2009, there is known a composition containing as an antiviral ingredient a glycyrrhizic acid salt, in particular ammonium glycyrrhizinate 0.25-1 wt.% And acceptable carriers and excipients.

The difference between the claimed invention and US 20090220440 A1 (1ST FARMACOTERAPICO IT SPA), 09/03/2009 in that the composition contains 0.001-0.5 wt.% Deoxyribonuclease (DNase) and has a complex antiviral effect, which consists in interrupting the replication of the virus in the early stages, stimulation of the release of the virion from the capsid, hydrolysis of viral DNA and the induction of interferon formation, as well as the suppression of secondary microflora and inflammation in the affected area and the acceleration of epithelization.

Pharmaceutical compositions containing the enzyme DNase and glycyrrhizic acid or its salts: ammonium glycyrrhizinate or dipotassium or trisodium, used in the prevention of viral infections are not described.

Thus, it is an object of the present invention to provide a pharmaceutical composition comprising a DNAase enzyme and glycyrrhizic acid or its salts: ammonium or dipotassium or trisodium glycyrrhizinate, which can be used to prevent viral infections caused by DNA-containing viruses, such like herpes, herpes zoster, human papilloma, adenoviruses and others.

The present invention provides a composition containing, as an active ingredient, 0.001-0.5 wt.% Deoxyribonuclease (DNase) 0.001-0.5 wt.% And glycyrrhizic acid or its salts: ammonium glycyrrhizinate or dipotassium or trisodium 0.001-0, 5 wt.% And acceptable carriers and excipients.

As a preferred embodiment of the claimed invention, there is provided a composition as defined above, further comprising an antimicrobial or antiviral ingredient.

Most preferred is a composition containing DNAase and either glycyrrhizic acid or its salts: ammonium glycirrhizinate or dipotassium or trisodium as the active ingredient and acceptable carriers and excipients, in the following ratio, wt.%:

DNAase 0.001-0.5

glycyrrhizic acid

or its salts: ammonium glycyrrhizinate

or dipotassium or trisodium 0.001-0.5 sanguirytrin or interferon or lysozyme 0.001-5.0 β-cyclodextrin or hydrogenated lecithin 0.001-5.0 preservative 0.5-1.0 polymer carrier 0.05-1.0 pH regulator 0.05-1.0 demineralized water 1.00-5.00 hydrophilic base 86.00-98.397

The active ingredients of the claimed pharmaceutical composition are the enzyme: DNAase and glycyrrhizic acid or its salts: ammonium glycyrrhizinate or dipotassium or trisodium. DNAase has the ability to inhibit the development of herpes viruses, adenoviruses and other DNA-containing viruses without damaging the DNA of macroorganism cells (Mashkovsky M.D. Medicines, Volume 2, Moscow, New Wave, 2000, pp. 111-112) . Glycyrrhizic acid and its salts are used as an antiviral agent for external and local use. Glycyrrhizic acid is active against DNA and RNA-containing viruses, including various strains of Herpes simplex, Varicella zoster viruses, human papilloma viruses, cytomegaloviruses. The antiviral effect is apparently associated with the induction of the formation of interferon. Interrupts the replication of viruses in the early stages, causes the virion to exit the capsid, thereby preventing its penetration into the cells. This is due to selective dose-dependent inhibition of phosphorylating kinase P. It interacts with the structures of the virus, changing various phases of the viral cycle, which is accompanied by irreversible inactivation of viral particles (which are in a free state outside the cells), blocking the introduction of active viral particles through the cell membrane into the cell, as well as impaired ability viruses to the synthesis of new structural components. Inhibits viruses in concentrations that are non-toxic to normally functioning cells. Virus strains resistant to acyclovir and iodouridine are highly sensitive to glycyrrhizic acid. It also has anti-inflammatory, analgesic and tissue regeneration-enhancing effects both in the early manifestations of viral infection and in ulcer forms. (http://www.vidal.ru/poisk_preparatov/act_1347.htm).

Interferon It is a highly purified sterile protein containing 165 amino acids. Identical to human leukocyte interferon alpha-2a. It has antiviral, antitumor and immunomodulating activity. It is possible that the mechanism of antiviral and antitumor activity is associated with a change in the synthesis of RNA, DNA and proteins. Inhibits virus replication in virus-infected cells. Increases the phagocytic activity of macrophages and enhances the specific cytotoxic effect of lymphocytes on target cells, (http://www.vidal.ru/poisk_preparatov/act_549.htm)

Sanguiritrin® has a wide spectrum of antimicrobial activity, acting on gram-positive and gram-negative bacteria (Staphylococcus spp., Streptococcus spp., Enterococcus spp., Shigella spp., Escherichia spp., Salmonella spp., Proteus spp., Acinetobacterpppppppp. , Pseudomonas spp., Serratia spp., Klebsiella spp., Antracoides spp., Cryptococcus spp.), Pathogenic fungi of the genus Microsporum, Trichophyton, Nocardia, Aspergillus, yeast-like fungi of the genus Candida (including polyresistant strains, Actince, and and some pathogenic protozoa (Entamoeba histolytica, Trichomonas vaginalis). The basis of the mechanism of the antimicrobial action of sanguirythrin is the suppression of bacterial nuclease, the violation of the processes of permeability of cell walls, division walls, nucleoid structure. http://www.vidal.ru/poisk_preparatov/sanguiritrin~21839. htm)

Lysozyme (from the Greek. Lysis - dissolution, decay and zyme - sourdough), muramidase, an enzyme of the hydrolase class; destroys the wall of the bacterial cell, resulting in its dissolution (lysis). In the body, it plays the role of a non-specific antibacterial barrier, especially in places of contact with the external environment (tears, saliva, nasal mucosa). Lysozyme was discovered in 1922 by A. Fleming in mucus from the nasal cavity and then found in many tissues and fluids of the human body (cartilage, spleen, white blood cells, tears), in plants (cabbage, turnip, radish, horseradish), in some bacteria and phages and , in the greatest quantity, in egg white. Lysozymes from different sources vary in structure, but are close in action. Egg protein lysozyme is the first enzyme for which a three-dimensional structure has been established by X-ray diffraction analysis and a relationship has been revealed between the structure and mechanism of action (1965); these studies are a significant contribution to the understanding of the mechanisms of enzymatic catalysis in general.

Lysozyme - a protein with a molecular weight of about 14,000; the only polypeptide chain consists of 129 amino acid residues and is folded into a compact globule (30'30'45 Å). The three-dimensional conformation of the polypeptide chain is supported by 4 disulfide (-SS-) bonds. (There are 3 of them in human milk lysozyme, 2 goose egg protein, 2 in goat T ₄ lysozyme; the more disulfide groups, the more stable but less active.) The lysozyme globule consists of two parts separated by a gap; in one part, most amino acids (leucine, isoleucine, tryptophan, etc.) contain hydrophobic groups, in others amino acids (lysine, arginine, aspartic acid, etc.) with polar groups predominate. The polarity of the environment affects the ionization of two carboxyl groups (-COOH) located on the surface of the gap of the molecule from different sides. Lysozyme acts on one of the main components of the bacterial wall - a complex polysaccharide consisting of two types of amino sugars. A polysaccharide is adsorbed on a lysozyme molecule in a gap on the border of its hydrophobic and hydrophilic parts in such a way that 6 amino sugar rings bind to the enzyme, and one of the glycosidic bonds connecting them (between 4 and 5 rings) is between the carboxyls. Due to the interactions between the carboxyls of lysozyme and the atoms forming the glycosidic bond, as well as the distortion of the bond angles of the substrate, the bond is activated and broken. This leads to destruction of the bacterial cell membrane.

(Phillips D., Three-dimensional structure of the enzyme molecule, in the collection: Molecules and cells, trans. From English, century 3, M., 1968; Protein chemistry, M., 1969; Bernhard S., Structure and function of enzymes, trans. . from English., M., 1971)

Thus, a complex antiviral effect is carried out: interruption of virus replication in the early stages, stimulation of the release of the virion from the capsid, hydrolysis of viral DNA and induction of interferon formation, as well as suppression of secondary microflora and inflammation in the affected area and acceleration of epithelization.

To prepare the composition, the enzyme preparation “Deoxyribonuclease” is used. The preparation was obtained from the pancreas of cattle by extraction from crushed raw materials, followed by purification and freeze drying. Lyophilized dried powder “Deoxyribonuclease” is used for herpetic keratitis and keratouveitis, acute catarrh of the upper respiratory tract of an adenovirus nature and pneumonia.

DNA-ase in the form of this preparation is not used for the treatment and prevention of viral infections due to its difficult absorption through intact skin and low level of consumer properties, as well as the lack of stability when the moisture content is more than 3% and in solution, with the loss of enzyme activity during the day.

Surprisingly, DNAase and hydrogenated lecithin or beta-cyclodextrin can be included in a stable composition while maintaining the activity of the enzyme for a long time, despite the fact that such a composition contains a significant amount of water (up to 5%).

The composition of the present invention is usually made by conventional methods using solid or liquid acceptable carriers or excipients selected from emulsifiers, dispersants, preservatives, flavorings, pH adjusters, polymer carriers and other excipients that are suitable for the preparation of compositions for topical use. The composition of the present invention can be prepared in the form of lipstick, injection, eye drops, suppositories, gel, cream, paste, ointment and the like.

Additional advantages of this composition are increased stability, potentiated complex antiviral effect, ease of use, as well as ease of dosing.

The claimed composition has stability with respect to the activity of the enzymes included in its composition during long-term storage, which is achieved by immobilization of enzymes on carriers contained in the specified composition. As these carriers, any lecithins, cyclodextrins and polymers capable of binding to enzymes to form enzyme-carrier complexes can be used. Examples of such polymeric carriers are gums, polyvinylpyrrolidone, carrageenans, sodium alginate, chitosan polyethylene glycol ether, sodium carboxymethyl cellulose, polyacrylate.

The activity of the claimed composition is due to the activity of the enzyme included in its composition and glycyrrhizic acid or its salts: ammonium glycyrrhizinate or dipotassium or trisodium. It was found that the composition for topical application, containing DNA ase 0.001-0.5 wt.%, Has stability with respect to the activity of the enzyme during its long-term storage, while the activity of this enzyme, prepared in the form of a solution, rapidly decreases. Glycyrrhizic acid or its salts: ammonium or dipotassium or trisodium glycyrrhizinate are stable compounds and do not require stabilization. Therefore, the claimed composition can be used for the effective prevention of DNA-containing viruses, such as herpes virus, herpes zoster, human papillomas, adenoviruses and others.

The present invention is illustrated by the following examples.

EXAMPLE 1

The composition in the form of a gel based on DNAase and ammonium glycyrrhizinate has the following composition:

DNAase 0.5 Ammonium Glycyrrhizinate 0.5 β-cyclodextrin 5,0 emulsifier 0.5 preservative 1,0 lysozyme 5,0 polymer carrier 1,0 pH regulator 1,0 demineralized water 85.50

The specified composition is prepared according to the following method. In demineralized water, DNase, β-cyclodextrin, ammonium glycyrrhizinate, lysozyme are dissolved, an emulsifier, a preservative, a polymeric carrier, and a pH regulator are added. The resulting gel is stirred, vacuum and homogenized.

EXAMPLE 2

The composition in the form of eye drops based on DNAase and dipotassium glycyrrhizinate has the following composition.

DNAase 0.001 Dipotassium glycyrrhizinate 0.001 Hydrogenated lecithin 0.001 emulsifier 0.5 preservative 1,0 interferon 0.001 polymer carrier 1,0 pH regulator 1,0 demineralized water 96,496

The specified composition is prepared according to the following method. In demineralized water, DNase, dipotassium glycyrrhizinate, interferon are dissolved, an emulsifier, a preservative, a polymeric carrier, hydrogenated lecithin, and a pH regulator are added. The resulting solution is filtered and sterilized.

EXAMPLE 3

The composition in the form of suppositories based on DNase and trisodium glycyrrhizinate has the following composition:

DNAase 0.5 Trisodium Glycyrrhizinate 0.5 β-cyclodextrin 2.0 emulsifier 0.5 preservative 1,0 sanguirythrin 2,5 polymer carrier 1,0 suppository base 86.0 pH regulator 1,0 demineralized water 5,0

The specified composition is prepared according to the following method. The suppository base is melted at a temperature of 40 ° C, DNAase, β-cyclodextrin, trisodium glycyrrhizinate, sanguirytrin are dissolved in demineralized water, an emulsifier, preservative, a polymeric carrier, and a pH regulator are added. The resulting mass is stirred, homogenized and poured into a mold and cooled.

EXAMPLE 4

The composition in the form of a solution for injection based on DNase and ammonium glycyrrhizinate has the following composition.

DNAase 0.001 Ammonium Glycyrrhizinate 0.001 Hydrogenated lecithin 0.001 emulsifier 0.5 preservative 1,0 interferon 0.001 polymer carrier 1,0 pH regulator 1,0 demineralized water 96,496

The specified composition is prepared according to the following method. In demineralized water, DNase, ammonium glycyrrhizinate, interferon are dissolved, an emulsifier, a preservative, a polymeric carrier, hydrogenated lecithin, and a pH regulator are added. The resulting solution is filtered and sterilized.

EXAMPLE 5

The composition in the form of a solution for injection based on DNase and ammonium glycyrrhizinate has the following composition.

DNAase 0.001 Ammonium Glycyrrhizinate 0.001 Hydrogenated lecithin 0.001 emulsifier 0.5 preservative 1,0 polymer carrier 1,0 pH regulator 1,0 demineralized water 96,495

The specified composition is prepared according to the following method. In demineralized water, DNase, ammonium glycyrrhizinate are dissolved, an emulsifier, a preservative, a polymeric carrier, hydrogenated lecithin, and a pH regulator are added. The resulting solution is filtered and sterilized.

EXAMPLE 6

Assessment of the stability of the enzyme.

Since the main disadvantage of DNAase is its instability in the presence of water from 3%, a comparative assessment was made of the conservation of enzyme activity during storage in the form of a solution and in the form of a composition for local use (for example, a gel).

DNAase activity was determined by the following procedure.

Determination of DNAase activity was carried out according to the Kunitz method. For the unit of activity, DNA-basics take the smallest amount of the enzyme, which, when exposed to the substrate under the experimental conditions, releases such an amount of acid-soluble products that leads to an increase in optical density at a wavelength of 260 nm per unit. 0.5 ml of substrate (DNA) and 0.3 ml of 0.2 M Tris buffer (pH = 7) are added to the control and two test tubes. In experimental, pre-warmed tubes, add 0.2 ml of the enzyme solution. Samples are thermostated for 30 minutes at a temperature of 37.5 ° C. Then, 1 ml of a 1N solution of perchloric acid (HClO ₄ ) cooled in an ice bath is added to the samples; 0.2 ml of the enzyme solution is added to the control. The tubes are shaken and kept in an ice bath for 16-25 minutes. The precipitates formed are separated by centrifugation at 4000 rpm for 10 minutes. 0.5 ml of solution was taken from the supernatant, 2.5 ml of water was added and the absorbance was measured at λ = 260 nm.

The results are shown in the following table.

Table 1 Test samples Main ingredients Storage stability one 2 3 Gel number 1 According to Example 1 DNase activity 90% for 5 years of observation Eye drops No. 2 According to Example 2 DNase activity 92% for 5 years of observation Suppositories No. 3 According to Example 3 DNase activity 92% for 5 years of observation Solution for injection No. 4 According to Example 4 DNAase activity 85% for 5 years of observation Solution for injection No. 5 According to Example 5 DNAase activity 85% for 5 years of observation Native enzyme solution (without carrier) - 5% activity for RNAase within 1 day

As can be seen from the table, the use of polymeric carriers and stabilizers in the composition makes it possible to obtain stable compositions while maintaining enzyme activity. During 5 years of observation, due to the creation of a stable conformation of the enzyme with β-cyclodextrin, hydrogenated lecithin and a carrier polymer.

EXAMPLE 7

The study of antiherpetic activity

The study was performed on white random-bred male mice weighing 18-20 g. In total, 120 animals were used in the experiments.

Herpes simplex virus type 2 (HSV-2), which causes an infection of urogenital localization in humans, was used to infect white mice. Therapy was started 2 hours after infection. Then the drugs were administered daily 1 time per day for 10 days in doses:

- The composition, according to EXAMPLE 4-5 ml / kg and 25 ml / kg intraperitoneally (0.1 ml and 0.5 ml per mouse, respectively).

- The composition according to EXAMPLE 2-100 mg / kg and 500 mg / kg rectally.

- Deoxyribonuclease (DNase) (freshly prepared 0.001 wt.% Solution in water for injection) - 5 ml / kg and 25 ml / kg intraperitoneally (0.1 ml and 0.5 ml per mouse, respectively).

- Isoprinosine - 500 mg / kg in the form of an aqueous suspension of tablets, based on the content of the active component in them. This dose is extrapolated to mice with the recommended daily dose for humans by multiplying by an interspecific transfer coefficient of 10.

The control group received distilled water (0.5 ml per mouse).

After 10-day quarantine, the animals were taken into an experiment to evaluate the effectiveness of drugs on a model of generalized herpetic infection. For this purpose, 6 groups of 16 animals each were formed.

For infection of animals, a herpes type 2 virus (HSV-2) was used, which causes an infection of urogenital localization in humans. Infectious material (the brain of sucker mice infected with HSV-2) was ground in a mortar in the cold, a 10% suspension was prepared, centrifuged at + 40 ° C (2000 rpm) for 20 minutes, and 10-fold dilutions were prepared. White mice were intraperitoneally infected.

Evaluation of the effectiveness of drugs was carried out according to 3 indicators:

a) mortality rate;

b) the percentage of protection (the difference in the level of survival in the experience and control of the virus);

c) average life expectancy (LSS).

The results are presented in table 2.

Therapeutic efficacy of drugs for generalized herpetic infection (HSV-2) in white mice

table 2 Group No. Preparations Dose, mg / kg (ml / kg) Palo / total in group % death % protection SPG (day) one. Isoprinosine 500 0/16 0 62.5 ∞

2. DNAase 25 6/16 37.5 25 12.4 3. DNAase 5 8/16 50.0 12.5 11.6 four. The composition according to EXAMPLE 5 25 4/16 25 37.5 43.4 5. The composition according to EXAMPLE 5 5 8/16 fifty 12.5 14.6 6. The composition according to EXAMPLE 2 500 0/16 0 62.5 ∞ 7. The composition according to EXAMPLE 2 one hundred 2/16 12.5 fifty 30.3 8. Control (group without treatment) 10/16 62.5 - 9.25

From the data of table 2 it follows that the administration to animals of the compositions of EXAMPLES 2 and 4 reduced the mortality rate of mice and increased the percentage of protection, which confirms the antiherpetic effect of the compositions.

The complex use of DNase with a glycyrrhizic acid salt showed greater antiherpetic efficacy compared to a DNAase solution.

Claims (3)

1. Composition for the treatment and prevention of viral infections caused by DNA-containing viruses, such as herpes, shingles, human papilloma, adenoviruses, containing as an active ingredient 0.001-0.50 wt.% Deoxyribonuclease (DNase) and 0.001- 0.50 wt.% Glycyrrhizic acid or its salts: ammonium or dipotassium or trisodium glycyrrhizinate, as carriers: 0.05-1.00 wt.% Polymer carrier, 0.001-5.00 wt.% Β-cyclodextrins or lecithins and acceptable excipients. 2. The composition according to claim 1, additionally containing sanguiryrin or interferon or lysozyme and acceptable excipients in the following ratio of components, wt.%:
DNAase 0.50 trisodium glycyrrhizinate 0.50 sanguirythrin 5.00 β-cyclodextrin 5.00 preservative 1.00 polymer carrier 1.00 pH regulator 1.00 demineralized water 5.00 suppository base 80.50 3. The composition according to claim 1, additionally containing 0.001-5.00 wt.% Sanguirytrin or interferon or lysozyme and acceptable excipients in the following ratio of components, wt.%:
DNAase 0.001 ammonium glycyrrhizinate 0.001 interferon 0.001 hydrogenated lecithin 0.001 preservative 1.00 emulsifier 0.50 polymer carrier 1.00 pH regulator 1.00 demineralized water 96,496